Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

Rhea-AI Summary

Pacira BioSciences (NASDAQ: PCRX) will present new real-world and health-economic data for EXPAREL at the AMCP Nexus 2025 Annual Meeting, Oct 27–30 in National Harbor, MD. Presentations on Oct 29 (12:00–1:00 p.m. ET) include results from the multicenter prospective IGOR registry and three posters evaluating EXPAREL's association with pain, opioid use, function, length of stay, healthcare utilization, and costs in total knee and outpatient shoulder arthroplasty settings.

Abstracts are available in the Journal of Managed Care + Specialty Pharmacy supplement.

-- Findings Presented at AMCP Nexus 2025 Annual Meeting --

BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world evidence evaluating the clinical effectiveness and economic benefits of EXPAREL^® (bupivacaine liposome injectable suspension) will be presented at the AMCP Nexus 2025 Annual Meeting taking place October 27–30 in National Harbor, Maryland.

One presentation includes new real-world evidence from the company’s Innovations in Genicular Outcomes Registry, or IGOR, a first-of-its-kind multicenter, prospective, longitudinal observational registry.

“Pacira continues to advance understanding of postsurgical pain management and the potential to reduce reliance on opioids,” said Jennifer Lin, Senior Director of Health Economics and Outcomes Research at Pacira BioSciences. “We look forward to continued exploration of multimodal pain pathways to help improve patient outcomes and potentially reduce downstream costs.”

Pacira Presentations at AMCP Nexus 2025

1. Intraoperative Liposomal Bupivacaine is Associated With Improved Pain, Opioid Use, Functional, and Length of Stay Outcomes After Total Knee Arthroplasty: Real-World Evidence
   Presenter: Jennifer Lin, Senior Director, Epidemiology in Health Outcomes Economics Research & RWE Department, Pacira BioSciences
   Poster Number: 1
   Date & Time: Wednesday, October 29, 12:00–1:00 p.m. ET
2. Clinical and Health Economic Outcomes With and Without Liposomal Bupivacaine in Medicare-Insured Patients Undergoing Outpatient Shoulder Arthroplasty
   Presenter: Gabriel Wong, Senior Director of Health Economics and Outcomes Research, Pacira BioSciences
   Poster Number: 3
   Date & Time: Wednesday, October 29, 12:00–1:00 p.m. ET
3. Impact of Liposomal Bupivacaine on Healthcare Resource Utilization and Costs in Patients Undergoing Total Knee Arthroplasty in Real-world Ambulatory Surgical Centers
   Presenter:
   Gabriel Wong, Senior Director of Health Economics and Outcomes Research, Pacira BioSciences
   Poster Number: 4
   Date & Time: Wednesday, October 29, 12:00–1:00 p.m. ET

Abstracts are available in the Journal of Managed Care + Specialty Pharmacy (JMCP) Supplement here.

About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

About EXPAREL® (bupivacaine liposome injectable suspension)
EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults. The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. The product combines bupivacaine with multivesicular liposomes, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

Important Safety Information about EXPAREL for Patients
EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. In the study where EXPAREL was given to children, the most common side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and/or loss of muscle movement. How much and how long the loss of feeling and/or muscle movement depends on where and how much of EXPAREL was injected and may last for up to 5 days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound, for patients younger than 18 years old, for injection near a nerve, and/or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the cardiovascular system; may cause an allergic reaction; may cause damage if injected into the joints; and can cause a rare blood disorder.

Forward-Looking Statements
Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: '5x30', our growth and business strategy, our future outlook, our intellectual property and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act, the expected cost savings and benefits of a July 2025 reduction in force and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including PCRX-201; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company and the anticipated funding or benefits of our share repurchase program. and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com                

Media Contact:
Kim Hamilton, (908) 391-0131
kim.hamilton@pacira.com

FAQ

When will Pacira (PCRX) present EXPAREL real-world data at AMCP Nexus 2025?

Pacira will present EXPAREL posters on Wednesday, October 29, 2025, 12:00–1:00 p.m. ET.

What topics will Pacira's (PCRX) AMCP Nexus 2025 presentations cover?

Presentations cover IGOR registry results and real-world outcomes on pain, opioid use, function, length of stay, utilization, and costs for knee and shoulder arthroplasty.

Which Pacira (PCRX) study is described as a multicenter prospective registry?

The Innovations in Genicular Outcomes Registry (IGOR) is described as a first-of-its-kind multicenter, prospective, longitudinal observational registry.

Where can investors read the abstracts for Pacira's (PCRX) AMCP Nexus presentations?

Abstracts are available in the Journal of Managed Care + Specialty Pharmacy (JMCP) supplement.

Who are the Pacira (PCRX) presenters for the EXPAREL posters at AMCP Nexus 2025?

Presenters listed include Jennifer Lin and Gabriel Wong, both senior directors in health economics and outcomes research.

Do Pacira's (PCRX) AMCP Nexus presentations include cost or utilization data for ambulatory surgical centers?

Yes; one poster evaluates the impact on healthcare resource utilization and costs for total knee arthroplasty in ambulatory surgical centers.